CD38: an immunomodulatory molecule in inflammation and autoimmunity

ZL Piedra-Quintero, Z Wilson, P Nava… - Frontiers in …, 2020 - frontiersin.org
CD38 is a molecule that can act as an enzyme, with NAD-depleting and intracellular
signaling activity, or as a receptor with adhesive functions. CD38 can be found expressed …

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology

F Malavasi, S Deaglio, A Funaro… - Physiological …, 2008 - journals.physiology.org
The membrane proteins CD38 and CD157 belong to an evolutionarily conserved family of
enzymes that play crucial roles in human physiology. Expressed in distinct patterns in most …

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression …

A Wiestner, A Rosenwald, TS Barry, G Wright… - Blood, 2003 - ashpublications.org
The presence or absence of somatic mutations in the expressed immunoglobulin heavy
chain variable regions (IgVH) of chronic lymphocytic leukemia (CLL) cells provides …

Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells

C Zhu, Z Song, A Wang, S Srinivasan, G Yang… - Frontiers in …, 2020 - frontiersin.org
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme
CD38, a protein highly expressed on hematological malignant cells, including those in …

Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity

S Deaglio, SC Robson - Advances in pharmacology, 2011 - Elsevier
Evolving studies in models of transplant rejection, inflammatory bowel disease, and cancer,
among others, have implicated purinergic signaling in clinical manifestations of vascular …

[HTML][HTML] Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy

KV Woan, H Kim, R Bjordahl, ZB Davis, S Gaidarova… - Cell Stem Cell, 2021 - cell.com
Select subsets of immune effector cells have the greatest propensity to mediate antitumor
responses. However, procuring these subsets is challenging, and cell-based …

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells

Y Wang, Y Zhang, T Hughes, J Zhang, MA Caligiuri… - Clinical Cancer …, 2018 - AACR
Purpose: Daratumumab and its use in combination with other agents is becoming a new
standard of care for the treatment of multiple myeloma. We mechanistically studied how …

ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia

J Dürig, H Nückel, M Cremer, A Führer, K Halfmeyer… - Leukemia, 2003 - nature.com
B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly
variable clinical course. Recent studies have shown that expression of the protein tyrosine …

The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors

JM Konen, JJ Fradette, DL Gibbons - Cells, 2019 - mdpi.com
The regulation of the immune microenvironment within solid tumors has received increasing
attention with the development and clinical success of immune checkpoint blockade …

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL

TD Shanafelt, SM Geyer, NE Kay - Blood, 2004 - ashpublications.org
Heterogeneity in the clinical behavior of patients with chronic lymphocytic leukemia (CLL)
makes it difficult for physicians to accurately identify which patients may benefit from an early …